Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy Followed by Atezolizumab in Stage II/III NSCLC
NCT04310020Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jan 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04310020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310020.